查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2099545

阿茲海默症診斷與治療市場 - 全球市場預測 2026-2032

Alzheimer's Disease Diagnostics & Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，阿茲海默症診斷和治療市場規模將達到 175.8 億美元，複合年成長率為 9.82%。

主要市場統計數據
基準年 2025 91.2億美元
預計年份：2026年 99.7億美元
預測年份 2032 175.8億美元
複合年成長率 (%) 9.82%

隨著醫療保健系統努力應對日益成長的失智症盛行率、發病年齡的提前以及對循證疾病修正治療日益成長的需求，阿茲海默症診斷和治療領域正處於關鍵時刻。這領域涵蓋認知功能評估、基於生物標記的診斷、神經影像學、腦脊髓液 (CSF) 檢測、血液衍生生物標記、數位化認知評估工具、澱粉樣蛋白和Tau標靶治療、症狀治療、護理支援技術，甚至包括專注於發炎、突觸健康、血管風險和神經保護的新方法。全球有超過 5500 萬人患有失智症，其中最常見的是阿茲海默症，因此早期診斷和建立有效的照護路徑是當務之急。一些市場對抗澱粉樣蛋白單株抗體的監管批准正在推動對早期檢測、患者分層、治療監測和多學科護理路徑的需求。然而，安全要求、管理能力、生物標記確認、保險報銷審查以及公平獲取仍然是主要阻礙因素。該行業正從專注於晚期疾病症狀管理的模式，轉向以早期診斷、生物標記檢驗、真實世界數據和協作治療決策為優先的阿茲海默症綜合護理連續體。

阿茲海默症領域的變革性變化

阿茲海默症的現況正因生物標記科學、精準神經病學和醫療保健系統重塑的融合而轉變。基於血液的生物標記研究，特別是與磷酸化Tau、澱粉樣蛋白病理和神經退化相關的檢測，正在加速以往依賴專科醫生評估、正子斷層掃描（PET）或腦脊髓液分析的臨床路徑。先進的影像技術持續支援診斷確認和治療合格評估，而數位化認知功能評估和遠端監測工具則有助於更好地追蹤疾病進展。在治療方面，從單純的症狀治療轉向緩解疾病策略正在重塑臨床方案，這要求進行澱粉樣蛋白識別、澱粉樣蛋白相關影像學觀察的風險評估以及治療後後續觀察。同時，訓練有素的記憶護理專家、靜脈輸液基礎設施、放射學檢查、與保險公司的合作以及病患教育的重要性也在不斷提升。最持久的進展有望來自一個綜合模型，該模型將準確的診斷、適當的治療選擇、看護者支持和在真實臨床環境中的標準化結果測量結合起來。

人工智慧對阿茲海默症護理的累積影響

人工智慧 (AI) 正整體成為阿茲海默症診斷和治療領域的累積驅動力，它能夠提升訊號檢測、工作流程效率和證據產生能力。在診斷領域，利用人工智慧分析磁振造影(MRI)、正子斷層掃描 (PET)、語音模式、電子健康記錄 (EHR)、穿戴式裝置數據和數位認知功能測試數據，可以更早識別風險並進行更持續的縱向監測。在治療領域，機器學習正被應用於病患分層、臨床試驗參與者篩選、標靶發現、安全性監測和疾病進展預測。人工智慧在臨床資源有限的情況下特別有用，決策支援工具能夠幫助確定轉診患者的優先順序並規範評估流程。然而，負責任地實施人工智慧需要檢驗的資料集、透明的演算法、偏差緩解措施、資料隱私保護、臨床監督以及符合醫療設備和軟體的監管要求。人工智慧的累積影響與其說是取決於單一工具本身，不如說是取決於醫療保健系統如何有效地將經過檢驗的見解整合到神經學工作流程、生物標記解釋、患者參與和真實世界證據收集中。

區域性對全球阿茲海默症診斷和治療的關鍵見解。

亞太地區人口老化速度加快，神經病學基礎設施不斷完善，對可擴展的失智症篩檢日益關注。日本、中國、韓國、澳洲和印度在臨床研究、診斷技術引進和護理模式發展方面各自發揮獨特的作用。日本長期以來重視國家失智症政策，中國不斷擴大醫院和研究基礎設施，而印度則需要低成本的社區篩檢，這些因素共同導致了阿茲海默症症診斷和治療準備程度的顯著差異。北美地區憑藉其完善的主導網路、生物標記研究基礎設施、疾病修正治療的監管途徑以及對真實世界數據（RWE）的積極利用，阿茲海默症。然而，由於醫療保險報銷政策、農村地區神經科短缺以及靜脈注射和影像檢查能力的限制，該地區獲得醫療保健服務仍然受到阻礙。在拉丁美洲，儘管失智症負擔日益加重，但獲得專科醫生、神經影像學檢查和生物標記檢測的機會卻不均等，因此，開展基層醫療教育、公眾意識提升以及建立經濟有效的診斷途徑至關重要。在歐洲，一些國家擁有成熟的失智症防治計畫、強大的神經病學學術網路以及不斷完善的醫療技術評估流程，但保險報銷制度、PET掃描的普及程度以及各國治療指南的差異正在影響治療方案的採納。在中東，失智症的診療工作正透過建立專科中心、投資醫院基礎設施以及提高公眾對老齡化相關神經系統疾病的認知而取得進展，尤其是在高所得的海灣國家。非洲面臨最嚴峻的醫療服務獲取障礙，包括對失智症的認知度低、專科醫生短缺以及獲得先進失智症方法的機會有限，因此，迫切需要開展社區篩檢、人力資源開發以及引入符合當地文化的認知功能評估工具。

影響阿茲海默症護理路徑發展的關鍵區域性見解

儘管東南亞國協在提高失智症認知和加強老年護理體系方面取得了進展，但在醫療保健資金、專家資源和診斷基礎設施方面仍然存在顯著差異，因此，可擴展的認知篩檢和轉診網路對於阿茲海默症的管理至關重要。在海灣合作理事會（GCC）國家，先進的醫療保健體係正在發展，神經學和影像學能力也在不斷提升，日益老化的人口凸顯了記憶診所、看護者支持和專家主導的治療路徑在政策層面的重要性。歐盟為阿茲海默症的診斷和治療提供了至關重要的監管和研究環境，跨境合作、資料管治框架和衛生技術評估（HTA）流程影響著生物標記檢測和新型療法的應用。金磚國家人口眾多，醫療需求各異，但醫療保健體系的成熟度卻不盡相同。中國和印度由於人口規模龐大，將在未來獲得診斷服務方面發揮核心作用，而巴西、俄羅斯和南非則面臨著與服務分配、經濟負擔和專家集中度相關的獨特挑戰。儘管七國集團在製定臨床指南、監管審查、應用先進影像技術、檢驗生物標記和生成真實世界證據方面處於領先地位，但成本效益、治療監測和公平獲取仍然是持續關注的問題。北約成員國的醫療保健系統與北美和歐洲的高所得國家的醫療保健系統高度重疊，在這些國家，失智症護理準備工作日益與人力資源規劃、數位醫療基礎設施和專科醫療服務的韌性密切相關。

各國在阿茲海默症診斷和治療方面的主要見解

美國擁有非常活躍的阿茲海默症生態系統，由專業中心、生物標記研究、監管活動和臨床試驗基礎設施提供支持，但實施過程中面臨的挑戰包括保險覆蓋範圍、治療監測、農村地區的醫療服務可及性以及靜脈注射能力。加拿大強調公共資助的醫療保健、記憶診所網路和實證評估，但不同地區獲得先進影像和專家會診的機會存在差異。在墨西哥和巴西，儘管對失智症的需求不斷成長，但專家的分佈並不均衡，因此，提高公眾宣傳活動、基層醫療培訓以及提供價格合理的診斷方法對於改善阿茲海默症護理至關重要。英國在失智症政策方面擁有豐富的經驗和強大的學術研究能力，但診斷瓶頸和醫療服務接收能力正在影響臨床推廣的速度。德國、法國、義大利和西班牙擁有強大的神經病學網路、針對老齡化社會的政策重點以及先進的醫院基礎設施，但國家保險報銷制度和醫療技術評估決策會影響基於生物標記的診斷和新療法的可及性。俄羅斯主要大都會地區擁有完善的神經系統醫療保健體系，但區域差異影響了診斷的一致性和先進檢測的可及性。中國正積極應對人口快速老化，增加對失智症的研究投入，提升醫院容量，並加大對生物標記的關注。同時，印度人口眾多，醫療保健資源分配不均，因此，低成本篩檢、看護者教育和可擴展的轉診系統顯得尤為重要。日本是老化程度最高的國家之一，高度重視失智症的政策制定，積極開展臨床研究，並已形成對早期發現和協調護理的明確需求。澳洲已建立失智症應對措施、學術研究和專業醫療保健網路，但農村和偏遠地區的醫療保健服務仍面臨挑戰。韓國正在推動國家失智症應對措施、引入數位醫療以及擴大專業醫療保健服務，以支持阿茲海默症的早期發現和系統化管理。

為阿茲海默症行業領導者提供的實用建議。

產業領導者應優先考慮整合阿茲海默症照護模式，該模式應將篩檢、生物標記確認、專家評估、治療合格判定、安全監測和看護者支持等環節連結起來。診斷技術開發人員應專注於臨床檢驗且擴充性的生物標記工具，以減少轉診延誤，同時維持高分析性能和清晰的解讀標準。治療領域的相關人員應使其產品策略與實際治療流程相符，包括影像功能、輸液物流、不利事件監測以及保險報銷的證據要求。醫療技術團隊應在不同人群中進行嚴格檢驗後方可實施人工智慧和數位認知工具，以減少偏差並提高臨床可靠性。醫療服務提供者和保險公司應合作制定流程，以便更早識別合適的患者，避免不必要的檢查，並支援協作決策。政策制定者應投資於失智症護理人員的培訓、公眾意識宣傳活動、患者登記系統以及公平獲取記憶護理服務。在整個價值鏈中，成功取決於臨床效用、病人安全性、營運可行性以及診斷準確性和護理結果的可衡量改進。

阿茲海默症診斷和治療的調查方法

本執行摘要基於結構化的二手研究方法，借鑒了檢驗的公共領域證據，包括同行評審的醫學文獻、監管公告、臨床實踐指南、公共衛生資訊來源、失智症政策文件以及公認的臨床研究途徑成果。調查方法強調在神經病學、老年醫學、診斷科學、數位健康和​​治療研發等領域進行三角檢驗，以確保阿茲海默症診斷和治療趨勢的平衡解讀。證據評估標準包括臨床相關性、監管可靠性、地理適用性和權威資訊來源的一致性。特別關注生物標記的發展、疾病修正治療的需求、人工智慧 (AI) 應用、區域醫療保健能力以及可及性問題。本分析不提供市場規模計算、預測、市場佔有率或未來展望；而是側重於定性的行業趨勢、檢驗的臨床進展以及對醫療保健相關人員的可操作性啟示。

結論：阿茲海默症診斷、治療和護理方面的進展

阿茲海默症的診斷和治療正邁向一個以早期檢測、基於生物標記的決策、人工智慧驅動的工作流程支援以及密切監測的緩解疾病治療路徑為特徵的新時代。最大的機會在於將科學進步轉化為可近、公平且臨床可靠的照護模式，使其能夠在專科醫療中心、社區和不同的區域醫療保健系統中有效運作。儘管先進的療法和生物標記正在改變人們的預期，但它們的影響取決於診斷系統的發展、安全監測、報銷調整、人力資源發展以及以患者為中心的溝通。能夠將檢驗的診斷方法、負責任的數位化創新、循證治療和切實可行的實施策略相結合的相關人員，將最有利於改善阿茲海默症症的照護。該領域的下一階段不僅取決於科學進步，還取決於能否為患者及其看護者提供及時的診斷、適當的治療和持續的支持。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：阿茲海默症診斷與治療市場：按產品分類

  • 診斷
    • 生物標記
      • 血液衍生生物標記
      • 腦脊髓液（CSF）生物標記物
    • 基因檢測
    • 影像技術
      • 電腦斷層掃描（CT）
      • 腦電圖（EEG）
      • 磁振造影（MRI）
      • 正子斷層掃描（PET）
    • 神經心理學測試
      • 確定失智症 8
      • 短期心理健康測驗（MMSE）
      • 蒙特婁認知評估
      • 神經精神病學症狀評定量表（NPI）
  • 治療
    • 聯合治療
    • 藥物治療
    • 非藥物療法
      • 行為干預
      • 認知刺激療法

第8章：阿茲海默症診斷與治療市場：按藥物類別分類

  • 膽鹼酯酶抑制劑
    • 多奈哌齊
    • Galantamine
    • Rivastigmine
  • 單株抗體
    • 阿杜卡奴單抗
    • 多納內馬
    • 利卡那單抗
  • NMDA受體拮抗劑

第9章：阿茲海默症診斷和治療市場：按患者群體分類

  • 65-74歲
  • 75-84歲
  • 85歲或以上
  • 65歲以下

第10章：阿茲海默症診斷與治療市場：依疾病階段分類

  • 阿茲海默症早期
  • 阿茲海默症晚期
  • 中度阿茲海默症

第11章：阿茲海默症診斷和治療市場：按最終用戶分類

  • 學術研究機構
  • 診斷中心
  • 居家照護環境
  • 醫院和診所

第12章：阿茲海默症診斷與治療市場：按分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：阿茲海默症診斷與治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：阿茲海默症診斷與治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：阿茲海默症診斷與治療市場：按國家分類

  • 美國
  • 中國
  • 德國
  • 英國
  • 日本
  • 加拿大
  • 印度
  • 俄羅斯
  • 義大利
  • 法國
  • 巴西
  • 墨西哥
  • 西班牙
  • 韓國
  • 澳洲

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbvie Inc.
  • AC Immune SA
  • Alector, Inc.
  • Alzheon, Inc.
  • Amylyx Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Biogen Inc.
  • BioXcel Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • Cognoptix Inc.
  • Corium Inc.
  • Danaher Corporation
  • Denali Therapeutics Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Grifols, SA
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Luye Pharma Group Ltd.
  • Merck & Co. Inc.
  • Muna Therapeutics
  • Novartis AG
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Company Limited
  • TauRx Therapeutics Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-742BD517AA98

The Alzheimer's Disease Diagnostics & Therapeutics Market is projected to grow by USD 17.58 billion at a CAGR of 9.82% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.12 billion
Estimated Year [2026] USD 9.97 billion
Forecast Year [2032] USD 17.58 billion
CAGR (%) 9.82%

Alzheimer's disease diagnostics and therapeutics are entering a decisive phase as healthcare systems confront rising dementia prevalence, earlier clinical presentation, and the growing need for evidence-based disease modification. The field spans cognitive assessment, biomarker-based diagnostics, neuroimaging, cerebrospinal fluid testing, blood-based biomarkers, digital cognitive tools, amyloid- and tau-targeted therapies, symptomatic treatments, care-support technologies, and emerging approaches focused on inflammation, synaptic health, vascular risk, and neuroprotection. According to the World Health Organization, more than 55 million people live with dementia globally, and Alzheimer's disease is the most common cause, reinforcing the urgency of timely diagnosis and effective care pathways. Regulatory approvals of anti-amyloid monoclonal antibodies in select markets have intensified demand for earlier detection, patient stratification, treatment monitoring, and multidisciplinary care pathways. At the same time, safety requirements, infusion capacity, biomarker confirmation, reimbursement scrutiny, and equitable access remain central constraints. The industry is shifting from a late-stage symptom-management model toward an integrated Alzheimer's care continuum that prioritizes timely diagnosis, biomarker validation, real-world evidence, and coordinated therapeutic decision-making.

Transformative Shifts in the Alzheimer's Disease Landscape

The Alzheimer's disease landscape is being transformed by the convergence of biomarker science, precision neurology, and health-system redesign. Blood-based biomarker research, particularly assays associated with phosphorylated tau, amyloid pathology, and neurodegeneration, is accelerating clinical pathways that historically depended on specialist evaluation, positron emission tomography, or cerebrospinal fluid analysis. Advanced imaging continues to support diagnostic confirmation and therapy eligibility, while digital cognitive assessments and remote monitoring tools are improving longitudinal disease tracking. Therapeutically, the transition from symptomatic-only care to disease-modifying strategies is reshaping clinical protocols, requiring amyloid confirmation, risk assessment for amyloid-related imaging abnormalities, and post-treatment surveillance. These shifts are also increasing the importance of trained memory-care specialists, infusion infrastructure, radiology access, payer alignment, and patient education. The most durable progress is expected from integrated models that combine accurate diagnosis, appropriate therapeutic selection, caregiver support, and standardized outcome measurement across real-world settings.

Cumulative Impact of Artificial Intelligence on Alzheimer's Care

Artificial intelligence is becoming a cumulative enabler across Alzheimer's disease diagnostics and therapeutics by improving signal detection, workflow efficiency, and evidence generation. In diagnostics, AI-enabled analysis of magnetic resonance imaging, positron emission tomography, speech patterns, electronic health records, wearable data, and digital cognitive testing can support earlier risk identification and more consistent longitudinal monitoring. In therapeutics, machine learning is being applied to patient stratification, trial enrichment, target discovery, safety surveillance, and prediction of disease progression. AI is particularly relevant where clinical capacity is limited, as decision-support tools can help prioritize referrals and standardize evaluation pathways. However, responsible adoption requires validated datasets, transparent algorithms, bias mitigation, data privacy safeguards, clinical oversight, and alignment with medical-device and software regulatory requirements. The cumulative impact of AI will depend less on standalone tools and more on how effectively health systems embed validated intelligence into neurology workflows, biomarker interpretation, patient engagement, and real-world evidence collection.

Key Regional Insights Across Global Alzheimer's Diagnostics and Therapeutics

Asia-Pacific is characterized by rapidly aging populations, expanding neurology capacity, and growing interest in scalable dementia screening, with Japan, China, South Korea, Australia, and India playing distinct roles in clinical research, diagnostic adoption, and care model development. Japan's long-standing national dementia policy focus, China's expanding hospital and research infrastructure, and India's need for low-cost community screening collectively make the region highly diverse in Alzheimer's disease diagnostics and therapeutics readiness. North America remains a leading region for advanced Alzheimer's diagnostics and therapeutics due to established specialist networks, biomarker research infrastructure, regulatory pathways for disease-modifying therapies, and strong use of real-world evidence; however, access remains shaped by reimbursement policies, rural neurology shortages, and capacity for infusion and imaging. Latin America faces increasing dementia burden alongside uneven access to specialists, neuroimaging, and biomarker testing, making primary-care education, public awareness, and cost-effective diagnostic pathways critical. Europe benefits from mature dementia strategies in several countries, strong academic neurology networks, and evolving health technology assessment processes, while variability in reimbursement, PET capacity, and national treatment guidelines influences adoption. The Middle East is advancing dementia care through specialist-center development, hospital infrastructure investment, and growing attention to aging-related neurological disease, particularly in high-income Gulf states. Africa faces the most significant access constraints, including limited dementia awareness, scarce specialist capacity, and restricted availability of advanced diagnostics, creating a strong need for community-based screening, workforce training, and culturally adapted cognitive assessment tools.

Key Group Insights Shaping Alzheimer's Disease Care Pathways

ASEAN countries are strengthening dementia awareness and geriatric care capacity, but wide differences in healthcare financing, specialist availability, and diagnostic infrastructure make scalable cognitive screening and referral networks essential for Alzheimer's disease management. The GCC is building advanced healthcare systems with growing neurology and imaging capabilities, and its aging populations are increasing the policy relevance of memory clinics, caregiver support, and specialist-led treatment pathways. The European Union provides an important regulatory and research environment for Alzheimer's diagnostics and therapeutics, with cross-border collaboration, data governance frameworks, and health technology assessment processes influencing the adoption of biomarker testing and novel therapies. BRICS countries combine substantial population need with diverse healthcare-system maturity; China and India are central to future diagnostic access because of demographic scale, while Brazil, Russia, and South Africa face distinct challenges related to service distribution, affordability, and specialist concentration. G7 countries are at the forefront of clinical guideline development, regulatory review, advanced imaging use, biomarker validation, and real-world evidence generation, though affordability, treatment monitoring, and equitable access remain ongoing concerns. NATO countries overlap significantly with high-income health systems in North America and Europe, where preparedness for dementia care increasingly intersects with workforce planning, digital health infrastructure, and resilience of specialist services.

Key Country Insights in Alzheimer's Disease Diagnostics and Therapeutics

The United States has a highly active Alzheimer's disease ecosystem supported by specialist centers, biomarker research, regulatory activity, and clinical trial infrastructure, while implementation challenges include payer coverage, treatment monitoring, rural access, and infusion capacity. Canada emphasizes publicly funded healthcare delivery, memory-clinic networks, and evidence-based assessment, with regional differences affecting access to advanced imaging and specialist consultation. Mexico and Brazil face rising dementia needs and uneven specialist distribution, making awareness campaigns, primary-care training, and affordable diagnostic approaches central to improved Alzheimer's care. The United Kingdom has established dementia policy experience and strong academic research capabilities, although diagnostic backlogs and health-service capacity influence the speed of clinical adoption. Germany, France, Italy, and Spain maintain robust neurology networks, aging-population policy focus, and advanced hospital infrastructure, with national reimbursement and health technology assessment decisions shaping access to biomarker confirmation and newer therapeutics. Russia has significant neurological care capacity in major urban centers, but geographic variation affects diagnostic consistency and access to advanced modalities. China is expanding dementia research, hospital capacity, and biomarker interest in response to rapid population aging, while India's large population and variable healthcare access heighten the importance of low-cost screening, caregiver education, and scalable referral systems. Japan is one of the most advanced aging societies, with high policy attention to dementia, strong clinical research activity, and established demand for early detection and care coordination. Australia combines dementia strategy, academic research, and specialist care networks with ongoing challenges in rural and remote access. South Korea is advancing national dementia initiatives, digital health adoption, and specialist services, supporting earlier identification and structured Alzheimer's disease management.

Actionable Recommendations for Alzheimer's Disease Industry Leaders

Industry leaders should prioritize integrated Alzheimer's care models that connect screening, biomarker confirmation, specialist evaluation, therapy eligibility, safety monitoring, and caregiver support. Diagnostic developers should focus on clinically validated, scalable biomarker tools that can reduce referral delays while maintaining high analytical performance and clear interpretation standards. Therapeutic stakeholders should align product strategies with real-world treatment workflows, including imaging capacity, infusion logistics, adverse-event monitoring, and evidence requirements for reimbursement. Health technology teams should deploy AI and digital cognitive tools only after rigorous validation across diverse populations to reduce bias and improve clinical trust. Providers and payers should collaborate on pathways that identify appropriate patients earlier, avoid unnecessary testing, and support shared decision-making. Policymakers should invest in dementia workforce development, public awareness, registries, and equitable access to memory-care services. Across the value chain, success will depend on demonstrating clinical utility, patient safety, operational feasibility, and measurable improvement in diagnostic confidence and care outcomes.

Research Methodology for Alzheimer's Disease Diagnostics and Therapeutics

This executive summary is developed using a structured secondary research approach grounded in verified public-domain evidence, including peer-reviewed medical literature, regulatory communications, clinical practice guidelines, public health sources, dementia policy documents, and recognized clinical research outputs. The methodology emphasizes triangulation across neurology, geriatrics, diagnostic science, digital health, and therapeutic development to ensure balanced interpretation of Alzheimer's disease diagnostics and therapeutics trends. Evidence was assessed for clinical relevance, regulatory credibility, geographic applicability, and consistency across authoritative sources. Particular attention was given to biomarker evolution, disease-modifying therapy requirements, artificial intelligence applications, regional healthcare capacity, and access considerations. The analysis avoids market sizing, market estimation, market share, and forecasting, focusing instead on qualitative industry dynamics, verified clinical developments, and actionable implications for healthcare stakeholders.

Conclusion: Advancing Alzheimer's Diagnosis, Treatment, and Care

Alzheimer's disease diagnostics and therapeutics are moving toward an era defined by earlier detection, biomarker-guided decision-making, AI-enabled workflow support, and carefully monitored disease-modifying treatment pathways. The greatest opportunities lie in translating scientific advances into accessible, equitable, and clinically reliable care models that work across specialist centers, community settings, and diverse regional health systems. While advanced therapies and biomarkers are changing expectations, their impact depends on diagnostic readiness, safety surveillance, reimbursement alignment, workforce training, and patient-centered communication. Stakeholders that combine validated diagnostics, responsible digital innovation, therapeutic evidence, and practical implementation strategies will be best positioned to improve Alzheimer's disease care. The sector's next phase will be measured not only by scientific progress but by the ability to deliver timely diagnosis, appropriate treatment, and sustained support for patients and caregivers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Alzheimer's Disease Diagnostics & Therapeutics Market, by Product

  • 7.1. Introduction
  • 7.2. Diagnostics
    • 7.2.1. Biomarkers
      • 7.2.1.1. Blood-Based Biomarkers
      • 7.2.1.2. Cerebrospinal Fluid (CSF) Biomarkers
    • 7.2.2. Genetic Testing
    • 7.2.3. Imaging Techniques
      • 7.2.3.1. Computed Tomography (CT) Scans
      • 7.2.3.2. Electroencephalogram (EEG)
      • 7.2.3.3. Magnetic Resonance Imaging (MRI)
      • 7.2.3.4. Positron Emission Tomography (PET)
    • 7.2.4. Neuropsychological Testing
      • 7.2.4.1. Ascertain Dementia 8
      • 7.2.4.2. Mini-Mental State Exam
      • 7.2.4.3. Montreal Cognitive Assessment
      • 7.2.4.4. Neuropsychiatric Inventory Questionnaire
  • 7.3. Therapeutics
    • 7.3.1. Combination Therapies
    • 7.3.2. Drug Therapies
    • 7.3.3. Non-Drug Therapies
      • 7.3.3.1. Behavioral Interventions
      • 7.3.3.2. Cognitive Stimulation Therapy

8. Alzheimer's Disease Diagnostics & Therapeutics Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Cholinesterase Inhibitors
    • 8.2.1. Donepezil
    • 8.2.2. Galantamine
    • 8.2.3. Rivastigmine
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Aducanumab
    • 8.3.2. Donanemab
    • 8.3.3. Lecanemab
  • 8.4. NMDA Receptor Antagonists

9. Alzheimer's Disease Diagnostics & Therapeutics Market, by Patient Demographics

  • 9.1. Introduction
  • 9.2. 65-74 Years
  • 9.3. 75-84 Years
  • 9.4. Above 85 Years
  • 9.5. Below 65 Years

10. Alzheimer's Disease Diagnostics & Therapeutics Market, by Disease Stage

  • 10.1. Introduction
  • 10.2. Early-Stage Alzheimer's
  • 10.3. Late-Stage Alzheimer's
  • 10.4. Middle-Stage Alzheimer's

11. Alzheimer's Disease Diagnostics & Therapeutics Market, by End User

  • 11.1. Introduction
  • 11.2. Academic & Research Institutes
  • 11.3. Diagnostic Centers
  • 11.4. Homecare Settings
  • 11.5. Hospitals & Clinics

12. Alzheimer's Disease Diagnostics & Therapeutics Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Alzheimer's Disease Diagnostics & Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Alzheimer's Disease Diagnostics & Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Alzheimer's Disease Diagnostics & Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. China
  • 15.3. Germany
  • 15.4. United Kingdom
  • 15.5. Japan
  • 15.6. Canada
  • 15.7. India
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. France
  • 15.11. Brazil
  • 15.12. Mexico
  • 15.13. Spain
  • 15.14. South Korea
  • 15.15. Australia

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbvie Inc.
  • 17.2. AC Immune SA
  • 17.3. Alector, Inc.
  • 17.4. Alzheon, Inc.
  • 17.5. Amylyx Pharmaceuticals, Inc.
  • 17.6. AstraZeneca PLC
  • 17.7. Aurobindo Pharma Limited
  • 17.8. Biogen Inc.
  • 17.9. BioXcel Therapeutics Inc.
  • 17.10. Bristol-Myers Squibb Company
  • 17.11. Cognoptix Inc.
  • 17.12. Corium Inc.
  • 17.13. Danaher Corporation
  • 17.14. Denali Therapeutics Inc.
  • 17.15. Eisai Co., Ltd.
  • 17.16. Eli Lilly and Company
  • 17.17. F. Hoffmann-La Roche AG
  • 17.18. GE Healthcare
  • 17.19. Grifols, S.A.
  • 17.20. H. Lundbeck A/S
  • 17.21. Johnson & Johnson Services, Inc.
  • 17.22. Lupin Limited
  • 17.23. Luye Pharma Group Ltd.
  • 17.24. Merck & Co. Inc.
  • 17.25. Muna Therapeutics
  • 17.26. Novartis AG
  • 17.27. Quest Diagnostics Incorporated
  • 17.28. Sanofi S.A.
  • 17.29. Siemens Healthineers AG
  • 17.30. Takeda Pharmaceutical Company Limited
  • 17.31. TauRx Therapeutics Ltd.
  • 17.32. Teva Pharmaceutical Industries Ltd.
  • 17.33. Thermo Fisher Scientific Inc.
  • 17.34. Voyager Therapeutics, Inc.
  • 17.35. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD-BASED BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD-BASED BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD-BASED BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CEREBROSPINAL FLUID (CSF) BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CEREBROSPINAL FLUID (CSF) BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CEREBROSPINAL FLUID (CSF) BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMAGING TECHNIQUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMAGING TECHNIQUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMAGING TECHNIQUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPUTED TOMOGRAPHY (CT) SCANS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPUTED TOMOGRAPHY (CT) SCANS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPUTED TOMOGRAPHY (CT) SCANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ELECTROENCEPHALOGRAM (EEG) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ELECTROENCEPHALOGRAM (EEG) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ELECTROENCEPHALOGRAM (EEG) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROPSYCHOLOGICAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROPSYCHOLOGICAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROPSYCHOLOGICAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ASCERTAIN DEMENTIA 8 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ASCERTAIN DEMENTIA 8 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ASCERTAIN DEMENTIA 8 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MINI-MENTAL STATE EXAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MINI-MENTAL STATE EXAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MINI-MENTAL STATE EXAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MONTREAL COGNITIVE ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MONTREAL COGNITIVE ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MONTREAL COGNITIVE ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-DRUG THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-DRUG THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-DRUG THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BEHAVIORAL INTERVENTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BEHAVIORAL INTERVENTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BEHAVIORAL INTERVENTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COGNITIVE STIMULATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COGNITIVE STIMULATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COGNITIVE STIMULATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHOLINESTERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHOLINESTERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHOLINESTERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DONEPEZIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DONEPEZIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DONEPEZIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GALANTAMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GALANTAMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GALANTAMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RIVASTIGMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RIVASTIGMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RIVASTIGMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADUCANUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADUCANUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADUCANUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DONANEMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DONANEMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DONANEMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL LECANEMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL LECANEMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL LECANEMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NMDA RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NMDA RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NMDA RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL 65-74 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL 65-74 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL 65-74 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL 75-84 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL 75-84 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL 75-84 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ABOVE 85 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ABOVE 85 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ABOVE 85 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BELOW 65 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BELOW 65 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BELOW 65 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL EARLY-STAGE ALZHEIMER'S MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL EARLY-STAGE ALZHEIMER'S MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL EARLY-STAGE ALZHEIMER'S MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL LATE-STAGE ALZHEIMER'S MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL LATE-STAGE ALZHEIMER'S MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL LATE-STAGE ALZHEIMER'S MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MIDDLE-STAGE ALZHEIMER'S MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MIDDLE-STAGE ALZHEIMER'S MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MIDDLE-STAGE ALZHEIMER'S MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 250. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 252. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 253. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 254. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 256. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 259. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 261. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. GCC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 294. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 295. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 296. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 297. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 298. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 299. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 301. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 302. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 303. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 304. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 305. G7 ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)

TABLE 3